Tata India Pharma & Healthcare Fund(IDCW-Payout)
Ticker: mf15827
Decent
48/100
☆ Add to Watchlist
More Options
T
Tata India Pharma & Healthcare Fund(IDCW)
The fund shows decent potential with consistent growth and profitability, but some risks in governance and execution need to be monitored.
View details
U
UTI Banking and Financial Services Fund(IDCW)
The UTI Banking and Financial Services Fund shows decent potential but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
View details
M
Mirae Asset Overnight Fund(M-IDCW)
The fund shows decent potential but is facing challenges in profitability and growth drivers.
View details
M
Mirae Asset Overnight Fund(W-IDCW)
The fund shows a decent performance with stable growth and a solid balance sheet, making it a reasonable investment option.
View details
M
Mirae Asset Overnight Fund(DD-IDCW)
The fund shows decent potential but lacks strong growth drivers and competitive advantages.
View details
A
Aditya Birla SL Income Plus Arbitrage Active FOF(IDCW)
The fund shows decent potential with moderate risks, but investors should be cautious about execution and liquidity issues.
View details
A
Aditya Birla SL Income Plus Arbitrage Active FOF(IDCW Payout)
The fund shows decent potential with stable growth prospects, but investors should be cautious of execution risks and liquidity issues.
View details
D
DSP Natural Res & New Energy Fund(IDCW)
The fund is positioned in a promising sector with decent growth potential, but execution risks and mixed market sentiment warrant caution.
View details
D
DSP Natural Res & New Energy Fund(IDCW-Reinv)
The fund shows potential in a growing sector, but investors should be cautious of execution risks and liquidity issues.
View details
F
Franklin India Dynamic Asset Allocation Active FOFs(IDCW Payout)
The fund presents a decent investment opportunity with moderate growth potential and manageable risks.
View details
F
Franklin India Dynamic Asset Allocation Active FOFs(IDCW)
The fund shows decent potential with moderate risks; however, investors should be cautious about execution and liquidity issues.
View details
E
Edelweiss Large Cap Fund(IDCW)
The Edelweiss Large Cap Fund shows potential but has several areas of concern that could impact future performance.
View details
H
HDFC Housing Opp Fund(IDCW)
The HDFC Housing Opp Fund shows potential for growth with a decent risk profile, but investors should be cautious of execution risks.
View details
H
HDFC Housing Opp Fund(IDCW Reinvest)
The fund shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
B
Bajaj Finserv Balanced Advantage Fund(IDCW)
The fund shows decent potential with a balanced approach, but investors should be cautious of market conditions and execution risks.
View details
B
Bajaj Finserv Small Cap Fund(IDCW)
Bajaj Finserv Small Cap Fund shows potential for growth but comes with notable risks and valuation concerns.
View details
Business Overview
The Tata India Pharma & Healthcare Fund (IDCW-Payout) is a dedicated mutual fund focusing on the dynamic pharmaceutical and healthcare sectors in India. Designed for investors seeking long-term growth, this fund capitalizes on the robust demand for healthcare solutions in a rapidly evolving market. With a strong management team and a commitment to quality, it aims to deliver attractive returns while ensuring stability.
- Focuses on the growing pharma and healthcare sectors
- Ideal for long-term investors
- Managed by experienced professionals
- Aims for attractive returns with stability
- Supports India's healthcare advancements
Investment Thesis
Tata India Pharma & Healthcare Fund stands out due to its strong promoter group, leveraging the Tata brand's credibility. The fund is well-positioned to capitalize on the growing digital services in healthcare. Additionally, its attractive valuation compared to peers makes it a compelling investment opportunity for retail investors looking for growth in the pharma sector.
- Backed by the reputable Tata Group, ensuring trust and stability.
- Significant growth potential in digital healthcare services.
- Attractive valuation compared to industry peers enhances investment appeal.
- Focus on innovative healthcare solutions aligns with market trends.
- Strong historical performance indicates reliable returns for investors.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare services
- Strong government support for pharma
- Innovative drug development pipeline
- Increasing health awareness among consumers
Risks ⚠️
- Regulatory changes affecting pricing
- High competition in the sector
- Dependency on foreign markets
- Potential supply chain disruptions
📊 Stock Investment Checklist (100 Points)
Tata India Pharma & Healthcare Fund(IDCW-Payout) • Updated: 2025-10-01 21:57:29
-
10BusinessHighPharmaceutical sector is future-ready with strong growth potential, but competition is intense.
-
10GrowthHighConsistent revenue growth observed, but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is not consistently higher than net profit.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
9GovernanceHighPromoter holding is strong with minimal pledging, good governance practices.
-
10DriversHighStrong growth drivers exist, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
The fund shows potential in a growing sector but faces challenges in profitability and valuation metrics. Caution is advised.